Chikungunya fever could be the next big global outbreak. Reassuringly, Themis’ vaccine has so far performed well in a Phase II study.
Vienna-based biotech, Themis, develops urgently needed vaccines against diseases, which have the potential to be the next global outbreak. The company has announced encouraging preliminary Phase II results for its vaccine against chikungunya fever. Next, Themis will hope that the study’s final results, which are expected in 2018 and 2019, continue to suggest that its vaccine could provide effective protection from the tropical disease.
Chikungunya fever is a viral infection transmitted by Aedes mosquitoes. It originates in Africa but increased global travel and rising temperatures have caused the mosquitoes carrying the virus to spread. Over the last four years, there have been over 1.7 million cases across 45 countries. The virus causes sudden fever and severe joint pain, which can become chronic.
Themis’ candidate is a modified measles vaccine that expresses antigens from the Chikungunya virus. The vaccine delivers the viral antigens directly to macrophages and dendritic cells, which triggers a strong immune response. The vector is able to replicate so continuously expresses antigens after immunization, resulting in long-term immunity.
Unfortunately, tropical diseases are often forgotten about until a major outbreak takes place and lives are lost. Thankfully, biotech has stepped in and is taking a number of different approaches to tackle these deadly diseases. Swiss biotech, Humabs, isolated an antibody against Middle East Respiratory Syndrome and has programs against Zika and Dengue viruses at the preclinical stage. Oxford University spin-out, Oxitec, has opened a factory in Brazil to continue producing a genetically engineered Aedes aegypti mosquito, which can limit the population size.
Earlier this year, Themis was boosted by a grant of £3M (€3.3M) from Innovate UK to push the vaccine towards Phase III, and it can be pleased with the progress made so far. The money from Innovate UK will help Themis to prepare for Phase III, by giving it the funds to conduct a small phase I study in the UK to validate the vaccine’s correlate of protection and identify a protective antibody threshold.
It is refreshing to see a company learning from our mistakes in the fight against previous outbreaks like Ebola and Zika. There has already been one major outbreak of Chikungunya fever back in 2015, so let’s hope that Themis has its vaccine ready if or when there is another.
Images – khlungcenter / shutterstock.com; Themis
This awesome article Austrian Biotech’s Vaccine Against Tropical Virus Moves Nicely Through Phase II appeared first on Labiotech.eu. Be kind and don’t copy it without asking 😉
What can art tell us about the mysteries of underwater life? Robertina Šebjanič explores the fascinating world of jellyfish, shrimps, fish and sea urchins.
Robertina Šebjanič is an artist and researcher fascinated by underwater life. Her work explores the relationship between humans and animals, often through an unusual medium: sound.
Šebjanič collaborates with other artists, philosophers, and marine researchers to explore the unexplored and complex world of underwater inhabitants, taking her audience closer to nature and encouraging us to reflect on our influence and relationship with other forms of life.
Aquatocene / Subaquatic quest for serenity
Armed with a hydrophone, Šebjanič has sailed across the Atlantic Ocean and the Aegean, Adriatic, and North Sea, recording a myriad of sounds coming from different species living underwater. The resulting soundscape compositions are beautiful immersive pieces that reveal there’s much more going on underwater than most of us tend to think.
But Šebjanič’s work also highlights how much sound pollution from humans there is in today’s aquatic ecosystems. “The more I recorded and listened to the material, the more I realized that these sounds are today’s sonic reality of the ocean and that there are not many places that are free of man-produced sounds,” the artist said in an interview.
Life underwater relies on sounds as much as terrestrial species to communicate, and their habitats can be severely affected by the ubiquitous use of ships, sonars, and sound cannons for oil exploration. Researchers studying this phenomenon have linked it with the beaching of whales and the Lombard effect, by which certain species become louder to overcome background noise, ultimately increasing the volume of the whole habitat.
You can listen to the audio compositions here.
Aurelia 1+Hz / proto viva sonification
The collaborating performers Robertina Šebjanič chose for this project are moon jellyfish. As the animals go about their business in an aquarium, a camera captures data of movement, contraction and interaction, which is then processed and used to navigate sound archives, coming mostly from underwater recordings of jellyfish bloom the artist did herself in Izmir, Turkey. The result is an audiovisual display in which the jellyfish and the artist perform together.
Jellyfish have existed for over 500 million years, adapting and surviving many changes in their habitat. Some species are known to be immortal. Not even human activity seems to disturb them, as it is happening with corals or fish. Šebjanič writes on her website that this could make this animal “one of the rare organisms that seem perfectly suited for the Anthropocene era,” able to survive the next mass extinction.
Through the project Aurelia 1+Hz / proto viva sonification, the artist looks into redefining our attitude towards interspecies collaboration. She reminds us that we humans are not the only ones on the planet with complex communication systems that equate to our language. To describe the piece, Šebjanič quotes Paul Celan: “There are still songs to sing beyond mankind.”
Upcoming events by Robertina Šebjanič
Performance: Aquatocene / Subaquatic quest for serenity
Tesla Award at City Museum Ljubljana, Slovenia
Exhibition: Aurelia 1+Hz / proto viva sonification
Cynetart festival, Dresden, Germany
16 – 19 November
Lecture: Sounds of Troubled Worlds = Songs for Serenity
Nonhuman agents in Art, Culture and Theory conference, Art Laboratory Berlin, Germany
AC Immune’s Anti-Tau antibody for the treatment of Alzheimer’s disease has reached Phase II, prompting milestone payments from Genentech.
Today, the first patient in a Phase II trial was dosed with AC Immune’s anti-Tau antibody for the treatment of Alzheimer’s disease. This triggered a milestone payment of CHF 14M (€12M) from its collaborator, Genentech, as part of an agreement worth more than CHF400M (€384M). AC Immune recently achieved an IPO of €52.5M on the NASDAQ and its market cap stands at $683M (€585M). The Phase II study will determine the antibody’s efficacy and safety.
AC Immune’s anti-Tau monoclonal antibody is based on the company’s SupraAntigen technology. They are generated by injecting the SupraAntigen constructs into mice and selecting antibodies that break up aggregated forms of misfolded proteins. The anti-Tau antibody has a high specificity for abnormal forms of the Tau protein and catches it as it moves in the extracellular space of the brain.
Within the Alzheimer’s field, it remains hotly debated whether abnormal tau proteins or amyloid-beta is the best approach to treating the disease. Tau proteins accumulate inside brain cells and then spread, while amyloid-beta forms plaques and oligomers around the outside of brain cells. But, AC Immune has covered all bases by also developing a SupraAntigen against amyloid-beta, Crenezumab, which is currently undergoing two phase III clinical trials.
Despite notable failures from Eli Lilly and Merck, AC Immune has chosen continue pursuing an antibody approach for the treatment of Alzheimer’s. The company has chosen a field that is searching frantically for a treatment or cure for a disease that is rapidly increasing in prevalence. Araclon Biotech’s vaccine and Probiodrug’s drug to prevent the formation of amyloid-beta plaques are currently offering some hope to the field.
Media – Orawan Pattarawimonchai / shutterstock.com; AC Immune
This awesome article Swiss Biotech Gets €12M as its Alzheimer’s Candidate Enters Phase II appeared first on Labiotech.eu. Be kind and don’t copy it without asking 😉
Until recently, cancer detection depended on invasive solid tissue sampling that didn’t provide a complete picture. These biotechs are making it easier to detect cancer early with liquid biopsies.
The notion that a person’s blood can reveal a wealth of health information looked so shiny that a company leading the charge, Theranos, was valued at $1B at its peak in 2014. Even though it has since come crashing down — the company recently listed its lab space for rent — efforts in the development of blood-based testing are going strong.
In particular, many companies are seeing success in the field of cancer diagnostics. “Oncology leads the way in blood diagnostics,” Dr. Ewan Hunter, Director of Business Development and Head of Statistics at Oxford BioDynamics, told me over the phone. His company analyses the environmental impact on the genome in the form of epigenetic DNA modifications. These modifications can then be used to screen for cancer, amongst other things.
Another company, QIAGEN, recently became the first to the European lung cancer market with its DNA-based technology: Therascreen enables VEGFR-based stratification of patients to determine if they are eligible for AstraZeneca’s Iressa. The product has since become the gold standard used in a majority of labs and clinics. Meanwhile, ANGLE has developed its own impressive test based on entire cells instead of fragments of DNA of dead cells, and it stands to become the new go-to for ovarian cancer.
So why did liquid biopsy development start in oncology? “The starting point to determine what’s possible is clinical need, and that’s currently personalizing care for people with cancer,” Andrew Newland, CEO of ANGLE, told me. Immuno-oncology therapies work for some but not all, and they’re expensive. “We have to ensure that the right patients receive the right therapy, and the way to do that is via liquid biopsy,” he continued.
Traditionally, testing is done with antibodies, but some cancers don’t have all the necessary surface markers, which the antibodies target to give a readout. Solid biopsies also have a major limitation: they can only be taken once, making it impossible to track progression over time. This is because tumors are heterogeneous and their genetic makeup changes over time, so the second sample won’t match the first. And if that’s not reason enough, solid biopsies are also highly invasive.
Liquid biopsies, on the other hand, can be done with a routine blood draw, and the technology has come so far that various tests are already on the market. Furthermore, these tests are at the forefront of the wave of personalized medicines. “We’re moving towards more targeted therapies by understanding molecular mechanisms,” said Michael Kazinski, Senior Director of Head of Global Product Management Sample Technologies at QIAGEN. And the best way to personalize a treatment in such a manner is to start with a liquid biopsy.
I talked to these leaders in the European space to hear about what their companies are doing the improve early cancer testing.
The Molecular Approach: Free Circulating DNA
QIAGEN began as a spin-out from the Heinrich Heine University in Düsseldorf with the aim of isolating nucleic acids. This core capability has been translated into technologies which allow identification via circulating DNA, whose primary use is in prenatal and oncological applications
QIAGEN became the first bring a diagnostic to the European market that uses them to stratify patients based on epithelial growth factor receptors, an important site of mutation in various cancers. Patients with mutations making for overactive EGFRs are eligible for treatment with AstraZeneca’s Iressa, an EGFR inhibitor.
“Liquid biopsy is nothing more than combining various technologies to identify biomarkers circulating in the blood and other body fluids, but it has the potential to revolutionize healthcare,” QIAGEN’s Michael Kazinski, told me. “What makes it amazing is its sheer accessibility.” Sampling a tumor might sound simple, but some cancers like those of the brain require drill holes into the skull.
This accessibility also makes it easier to catch the disease earlier and monitor patients and their disease progression. “When you can see a tumor on PET scans or other imaging technologies, for example, it’s already very late in cancer progression,” explained Kazinski. “If you can identify the disease earlier, especially if it has resistant mutations, you can adapt a therapy to a patient,” he elaborated. “You can make it much more effective that way, and you can keep repeating the process to monitor the treatment’s efficacy.”
The next step for QIAGEN is to bring NGS and bioinformatics into the mix: the company hopes it will help to parse huge amounts of data allowing researchers to find correlations between genes and disease onset or progression. In addition, QIAGEN has developed a full suite of solutions covering PCR and NGS based analysis of circulating RNA, exosomes, and CTCs. When I asked about stumbling blocks, Kazinski told me they depend on the application: “Is there a sufficient amount of DNA? Will the test be reimbursed? We’re working through them, indication by indication.”
Oxford BioDynamics goes a step further than direct DNA sequence analysis by looking at regulatory genome architecture — that is, expression and silencing of genes via epigenetic mechanisms, specifically the changes in structure-function of the 3D genome organization. The company’s CSO, Alexandre Akoulitchev, said that these biomarkers are increasingly recognized as being highly informative for patient stratification:“In many indications, particularly in oncology, we demonstrate a very high correlation between disease manifestation and the molecular regulatory systems, which are all reflected in the abnormal genome architecture.”
The company’s platform, EpiSwitch, monitors systemic abnormal epigenetic signatures that are found in the cells present in a blood sample of someone with a particular disease or pathology. Based on this, EpiSwitch can identify, validate and monitor epigenetic biomarkers known as ‘Chromosome Conformation Signatures’ that represent an individual’s state of genome regulation, including its gene expression, genetic risks, and even metabolic state.
Chromatin conformations can be used to effectively stratify patients, as a group of researchers at the Mayo Clinic successfully demonstrated in a group of melanoma patients. Using a noninvasive test based on chromatin conformation biomarkers, the team was able to determine if a patient had melanoma, from early to late stage, and discriminate these patients from healthy controls or patients with non-melanoma skin lesions.
When I asked Akoulitchev why epigenetics is the best approach with the dawn of cell-based technologies, he explained that the value of epigenetics is that, “these markers are reflective of responses to the environment, and looking at this is essential. Reading the genome architecture using EpiSwitch proves to be much less noisy compared to other biomarker modalities, which include continuous ranges of readouts and stochastic noise, thus making the data hideously complicated.”
Oxford BioDynamics is focusing on immuno-oncology for now, although the applications of EpiSwitch are broad, with oncological, neurological and autoimmune indications all on the table. Akoulitchev said, “We’re agnostic when it comes to which disease areas, treatments, and patient stratifications to advance with EpiSwitch.”
The Cellular Approach
ANGLE leverages its circulating tumor cell (CTC) technology in its first clinical application to detect ovarian cancer. Ovarian cancer is particularly tricky to diagnose and as a result, many women do not receive the treatment they need. In the United States alone, over 750,000 women each year are diagnosed with an abnormal pelvic mass. Of these, around 200,000 will have surgery to remove the pelvic mass, with around 10 percent of those having surgery will have ovarian cancer.
For a benign mass, the surgery is straightforward — a one-hour operation, often key-hole surgery, after which the patient can sometimes go home on the same day; but ovarian cancer has to be treated much more carefully. It requires open surgery — six hours on the table and perhaps a week of intensive care afterwards — and care not to spread the cancer to other parts of the body. Naturally, if there’s a chance a tumor is malignant, patients and doctors will opt for the latter as patients with ovarian cancer who do not receive this specialist care usually have a poor outcome.
ANGLE is working to implement its Parsortix system to detect ahead of surgery which patients have cancer and to help doctors make more informed decisions to ensure patients receive the specialist care they need.
So how does the Parsortix technology work? “ANGLE pioneers the collection of living cancer cells from patient blood for analysis,” Newland told me. Traditionally, liquid biopsies hinge on dead cancer cell fragments, CTDNA, which doesn’t provide any data on RNA or protein expression. “This approach has not worked to detect ovarian cancer,” commented Newland.
Alternative approaches evaluating proteins in the blood suffer from low specificity with a high number of false positives. He pointed to Austin-based Vermillion and its ovarian cancer test, OVA1, as an example: OVA1 relies on a protein called CA125 and only between one sixth and one fifth of its positives are true positives. This is because while Vermillion’s technology boasts a high sensitivity of 92%, its specificity is low — only 54% — and proteins like CA125 can be upregulated for benign reasons instead of cancer.
“They’re looking at byproducts, not the actual cancer itself,” explained Newland.
Compared to OVA1, ANGLE’s Parsortix assay has the potential to provide similar high sensitivity but with a much higher specificity, with low false positives. And now that ANGLE has acquired Axela, it can leverage the Canadian company’s technology to analyze up to 100 genes simultaneously in what’s called a “sample-to-answer” process to quickly obtain a diagnosis.
“Axela’s technology has similar utility to NGS but for a much lower price,” remarked Newland, citing $50 to $100 per run compared to the millions it costs to maintain and run one of Illumina’s machine. The alternative approach is to use PCR: this comes with a much lower cost but it’s limited on a practical basis to only about 8 genes per sample, which is not enough for key clinical applications. ANGLE’s new Axela platform can run 100 genes at a similar price to PCR.
The present challenge for ANGLE isn’t competitors, Newland told me. Indeed, ANGLE seems to have a friendly relationship with another liquid biopsy leader, QIAGEN, as they signed a co-marketing partnership in September this year. Rather the major focus for ANGLE is completing the necessary clinical studies and pushing forward to regulatory approval.
“We’re hoping to be the first-ever FDA-approved live cell liquid biopsy in cancer,” Newland said. The final step, a 400-patient trial with MD Anderson is expected to be completed by the end of Half 1 in 2018; if the results are positive, ANGLE is well-positioned for launch.
Thanks to all of the interviewees for patiently answering my questions! Which companies would you have added? Comment below!
Images via donfiore, Carl Dupont, Evgeniy Kalinovskiy, Christoph Bergstedt, Kateryna Kon, RAJ CREATIONZS / shutterstock.com
This awesome article Detecting Cancer Early: A Review of Liquid Biopsies appeared first on Labiotech.eu. Be kind and don’t copy it without asking 😉
The Dutch Design Week featured several biodesign projects that explore how the future will be shaped by the advance of biotechnology. Let’s have a look at some of them.
Celebrated annually in Eindhoven, the Dutch Design Week has become a hotspot where designers share the latest trends and technologies. In the last few years, biodesign is increasingly drawing the attention as synthetic biology techniques are revolutionizing the way we produce and work with materials, often as a sustainable alternative to traditional methods.
Adidas is already producing biodegradable silk sneakers made in bioreactors and Coca-Cola is working on renewable bioplastic bottles. So what were the latest innovations presented this year at the Dutch Design Week?
Bioanarchy in the UK
Synthetic biology techniques become more and more accessible. For example, thanks to Bento Bio, you can already buy your own kit to analyze DNA samples at home. But what will happen when anyone can edit DNA at home?
In a workshop titled Biodesign for Social Impact, a team of students from the University of Edinburgh presents the potential of biotechnology to take over the social and political landscapes in the near future. Their project UK 2029, which won the runner-up award at the BioDesign Challenge 2017, imagines a future where the United Kingdom allows the release of GMOs, leading anarchist biohackers to use genetically modified fungi to fight gentrification and to create skin implants to hide microbial factories from the government’s microbial surveillance technology.
Biocurrency and fungal paint
The Material Sense LAB in Eindhoven develops biomaterials adapted to the needs of the future. “We want to leave behind as little waste as possible,” says founder Simone de Waart. At the Dutch Design Week, one of the projects it presents is a new form of bio-based currency. The coins, made of bioplastic PLA, have already been successfully used as payment during the Gebouw-T festival.
Another project is Xyhlo bio-finish, a black paint made out of a type of fungus called Aureobasidium pullulans. This black fungus can tell how healthy the wood of the trees it lives on is, depending on how dark its color is. This allows assessing when the material is at the end of its lifecycle, which can then be re-used for other applications. Three buildings in the Netherlands have already been painted with Xyhlo bio-finish and the Material Sense LAB is following how it holds up.
Carbios and L’Oréal have had enough of the plastics bags and packaging littering our streets and will form a consortium for the bio-recycling of plastic on an industrial scale.
Today, you’ll struggle to walk along a street without seeing plastic bottles, bags, and wrappers dropped by the wayside… but thankfully, help is at hand. Carbios, a pioneer in the bioplasturgy field, has joined forces with cosmetics giant L’Oréal to tackle plastic pollution. The two companies will form a consortium that will work over five years to bring Carbios’ bio-recycling technology to market on an industrial scale.
Companies from any other sectors will be able to join the consortium. Fingers crossed this will signal a change in the way we use and produce plastics.
Each year, 8 million tons of plastic is dumped in the oceans, so it really is time to do something about plastic waste. Carbios has developed technology that, for the first time in history, will allow plastic to be recycled over and over again — all thanks to the natural action of the company’s special enzymes. Carbios is targeting plastics like polyethylene terephthalate and polylactic acid, which are commonly used for bottles, packaging and films.
Most plastic recycling processes rely on high temperatures and a lot of energy, but Carbios’ system simply uses enzymes to break down plastics into their original monomers. Once separated and purified, these same monomers can be re-used to produce new plastic — all without a costly recycling process.
The companies in the consortium will be the first to receive Carbios’ technology once it becomes available. L’Oréal will use the bio-plastic when it designs its new packaging, promoting it to many other companies and industries. “It’s a wonderful opportunity to protect the environment, and this consortium will also help boost the circular economy,” stated Philippe Thuvien, Packaging & Development VP at L’Oréal.
More and more, big firms like L’Oréal seem to interested in turning green. Coca-Cola and Danone are working with Dutch biotech Avantium to develop sustainable bottles and yogurt cups, while Audi is collaborating with the French Global Bioenergies for the production of renewable gasoline. Even Lego is working on making its famous toys with bioplastics. Their involvement with renewable materials and energy is a great example for the many smaller companies that aspire to follow their steps.
Images – Sokolenko / shutterstock.com; Carbios
This awesome article French Biotech Gets Together with L’Oréal to Clean up our Streets appeared first on Labiotech.eu. Be kind and don’t copy it without asking 😉
The FDA has granted orphan drug designation to Shire’s hemophilia A gene therapy, giving it the boost it needs to catch up with others in the field. Shire specializes in the development of drugs for rare diseases, including hemophilia A …
This awesome article Shire’s Hemophilia Gene Therapy Boosted by Orphan Drug Designation appeared first on Labiotech.eu. Be kind and don’t copy it without asking 😉
TiGenix has seen its Crohn’s disease candidate receive orphan drug designation after agreeing on a global Phase III trial. TiGenix exploits the anti-inflammatory properties of donor-derived stem cells to treat diseases. One of its candidates, Cx601, is targeted at Crohn’s disease – …
This awesome article FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation appeared first on Labiotech.eu. Be kind and don’t copy it without asking 😉
An exhibition “not for the squeamish” at Science Gallery London explores the fascinating world of blood: its history, the science and our relationship to it. Blood is essential to keep us alive. Our own language shows us that it has …
This awesome article Blood Takes the Stage at a Science and Art Exhibition in London appeared first on Labiotech.eu. Be kind and don’t copy it without asking 😉
Inbiomotion has published the results of a Phase III study looking at its MAFTest to personalized approaches to the disease. Inbiomotion, based in Barcelona’s biotech hub, works on a highly selective biomarker for breast cancer. A Phase III study demonstrated that …
This awesome article Personalized Breast Cancer Treatment Coming Soon with Help from Spanish Biotech appeared first on Labiotech.eu. Be kind and don’t copy it without asking 😉